Actelion

Idorsia drug fails to quell binge eating in midphase trial, driving biotech to abandon the indication
Idorsia drug fails to quell binge eating in midphase trial, driving biotech to abandon the indication
Fierce Biotech
Idorsia
clinical trials
ACT-539313
binge eating disorder
Actelion
Flag link:
Top 10 pharma settlements since 2018
Top 10 pharma settlements since 2018
Fierce Pharma
settlements
Reckitt Benckiser
JNJ
Bayer
Allergan
Actelion
Purdue Pharma
Teva Pharmaceutical
Endo
Teikoku
Insys
Pfizer
GSK
Astellas
Amgen
Flag link:
Actelion inks $360M deal to resolve DOJ kickbacks probe
Actelion inks $360M deal to resolve DOJ kickbacks probe
Fierce Pharma
JNJ
DOJ
PAH
Actelion
kickbacks
Flag link:
After split from Actelion, Idorsia CEO plans to raise more cash in 2019
After split from Actelion, Idorsia CEO plans to raise more cash in 2019
Yahoo/Reuters
Indorsia
Actelion
JNJ
insomnia
Flag link:
FDA calls out 39 drug companies for allegedly blocking access to generics
FDA calls out 39 drug companies for allegedly blocking access to generics
Stat
JNJ
Actelion
Celgene
Gilead
Novartis
Pfizer
Valeant Pharmaceuticals
generics
FDA
Flag link:
J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout
J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout
Endpoints
JNJ
Actelion
antibiotics
C. difficile
cadazolid
Flag link:
Biotech sector ensures highest premium among M&A transactions
Biotech sector ensures highest premium among M&A transactions
GoinPharma
biotech
M&A
Kite Pharma
Gilead Sciences
JNJ
Actelion
Flag link:
J&J adds PhIII hypertension drug to the pipeline with $230M-plus cash deal for Idorsia
J&J adds PhIII hypertension drug to the pipeline with $230M-plus cash deal for Idorsia
Endpoints
JNJ
hypertension
Idorsia
Actelion
Flag link:
Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?
Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?
Motley Fool
biotech
M&A
JNJ
Actelion
Takeda
Ariad Pharmaceuticals
Gilead Sciences
Pfizer
Amgen
Flag link:
Johnson & Johnson closes $30B Actelion buyout
Johnson & Johnson closes $30B Actelion buyout
Drug Delivery Business News
JNJ
Actelion
M&A
Flag link:
Johnson & Johnson wins last regulatory nod needed for Actelion acquisition
Johnson & Johnson wins last regulatory nod needed for Actelion acquisition
Drug Delivery Business News
JNJ
Actelion
M&A
EU
Europe
Flag link:
Johnson & Johnson’s $30B buyout suffers setback as Actelion antibiotic fails in one phase 3, succeeds in another
Johnson & Johnson’s $30B buyout suffers setback as Actelion antibiotic fails in one phase 3, succeeds in another
Fierce Biotech
JNJ
Actelion
clinical trials
M&A
antibiotics
cadazolid
Flag link:
Minerva shares jump as J&J hands over $30M, revises insomnia drug pact; Iroko lays off 122
Minerva shares jump as J&J hands over $30M, revises insomnia drug pact; Iroko lays off 122
Endpoints
Minerva Neurosciences
MIN-202
JNJ
Actelion
insomnia
Iroko Pharmaceuticals
Flag link:
Johnson & Johnson: Help Me Actelion, You're My Only Hope
Johnson & Johnson: Help Me Actelion, You're My Only Hope
Barron's
JNJ
Actelion
M&A
earnings
Flag link:
About that pharma M&A comeback? Sorry. 2017's not bringing it—at least not yet
About that pharma M&A comeback? Sorry. 2017's not bringing it—at least not yet
Fierce Pharma
M&A
Stada
Shire
Baxalta
JNJ
Actelion
Mylan Labs
Pfizer
Takeda
Ariad Pharmaceuticals
Medivation
Flag link:
3 Big Pharma Companies With the Best Pipelines
3 Big Pharma Companies With the Best Pipelines
Motley Fool
JNJ
Actelion
Darzalex
Novartis
Cosentyx
Jakavi
Lucentis
Tasigna
Roche
Venclexta
Tecentriq
emicizumab
Flag link:
Actelion shareholders OK R&D spinout
Actelion shareholders OK R&D spinout
Drug Delivery Business News
Actelion
R&D
spinoffs
JNJ
Flag link:
JNJ Declares Success of Actelion Tender, Sees Closing in Second Quarter
JNJ Declares Success of Actelion Tender, Sees Closing in Second Quarter
TheStreet.com
JNJ
Actelion
M&A
Flag link:
4 Reasons Johnson & Johnson Surged 8% in February
4 Reasons Johnson & Johnson Surged 8% in February
Motley Fool
JNJ
Darzalex
Actelion
Donald Trump
Flag link:
What's wrong with Sanofi's dealmaking approach? To hear Actelion tell it, plenty
What's wrong with Sanofi's dealmaking approach? To hear Actelion tell it, plenty
Fierce Pharma
Sanofi
Actelion
M&A
Flag link:

Pages